Showing results (121-130 of 158) with videos related to
Sort By:
Pageof 16
Current Cardiology Reports|August 19, 2021
Pregnancy-Associated Myocardial Infarction: A Review of Current Practices and GuidelinesAnas Alameh, Ahmad Jabri, Wesam Aleyadeh, et al.American Heart Journal|April 29, 2006
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trialMatthews Chacko, A Michael Lincoff, Katherine E Wolski, et al.American Heart Journal|April 4, 2025
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)Leslie Cho, Stephen J Nicholls, Børge G Nordestgaard, et al.Diabetes Care|September 6, 2014
High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURNBrian Stegman, Rishi Puri, Leslie Cho, et al.Journal of Cardiovascular Magnetic Resonance : Official Journal of the Society for Cardiovascular Magnetic Resonance|February 23, 2022
Sex-based differences in left ventricular remodeling in patients with chronic aortic regurgitation: a multi-modality studyAlbree Tower-Rader, Isadora Sande Mathias, Nancy A Obuchowski, et al.Nature Communications|January 25, 2020
Genetic deletion of mast cell serotonin synthesis prevents the development of obesity and insulin resistanceJulian M Yabut, Eric M Desjardins, Eric J Chan, et al.American Journal of Preventive Cardiology|July 30, 2021
C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOVAdam J Nelson, Rishi Puri, Danielle M Brennan, et al.American Journal of Preventive Cardiology|August 10, 2021
Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]Adam J Nelson, Rishi Puri, Danielle M Brennan, et al.American Heart Journal|June 7, 2016
Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)Rishi Puri, Steven E Nissen, Ransi Somaratne, et al.Journal of the American College of Cardiology|May 14, 2013
Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reportingBhuvnesh Aggarwal, Stephen G Ellis, A Michael Lincoff, et al.Pageof 16